RELAY THERAPEUTICS INC. - COMMON STOCK

Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

04 Aug 2022 13:05:03 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

28 Jul 2022 13:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

27 Jun 2022 03:00:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event

16 Jun 2022 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

26 May 2022 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

05 May 2022 13:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference

03 May 2022 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights

28 Apr 2022 13:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

24 Feb 2022 13:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

17 Feb 2022 13:05:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

02 Feb 2022 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008

04 Jan 2022 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination

10 Dec 2021 04:30:00 By Nasdaq GlobeNewswire

Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

10 Nov 2021 13:05:01 By Nasdaq GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights

04 Nov 2021 13:05:02 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

12 Oct 2021 18:58:23 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Proposed Public Offering of Common Stock

11 Oct 2021 13:15:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor

08 Oct 2021 03:00:00 By Nasdaq GlobeNewswire

Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα

07 Oct 2021 05:50:00 By Nasdaq GlobeNewswire